Last update 09 Jul 2025

Redasemtide Trifluoroacetate

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Redasemtide, S 005151, S-005151
Target
TRIM2
Action
modulators
Mechanism
TRIM2 modulators(tripartite motif containing 2 modulators), Stem cells modulators
Therapeutic Areas
Immune System DiseasesNervous System DiseasesCardiovascular Diseases+ [4]
Active Indication
Ischemic cardiomyopathyAcute Ischemic StrokeEpidermolysis Bullosa Dystrophica+ [2]
Inactive Indication-
Originator Organization
StemRIM, Inc.StemRIM, Inc.
Active Organization
Shionogi & Co., Ltd.Shionogi & Co., Ltd.Fuji Yakuhin Co., Ltd.Fuji Yakuhin Co., Ltd.StemRIM, Inc.StemRIM, Inc.
Inactive Organization-
License Organization
StemRIM, Inc.StemRIM, Inc.Shionogi & Co., Ltd.Shionogi & Co., Ltd.
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (Japan)
Login to view timeline

Structure/Sequence

Related

7
Clinical Trials associated with Redasemtide Trifluoroacetate
JPRN-jRCT2051240065
/ RecruitingPhase 1/2IIT
Parallel-group, placebo-controlled study to evaluate the safety, tolerability, and efficacy of repeated intravenous administration of S-005151 to patients with ischemic cardiomyopathy undergoing coronary artery bypass surgery (Phase I/II)
NCT05953480
/ RecruitingPhase 2
A Phase 2b, Multinational, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Redasemtide (S-005151) Compared With Placebo in Adult Participants With Acute Ischemic Stroke Who Are Not Eligible for Tissue Pasminogen Activator or Thrombectomy
JPRN-jRCT2031230083
/ RecruitingPhase 2IIT
A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S 005151) compared with placebo in adult participants with acute ischemic stroke who are not eligible for tissue plasminogen activator or thrombectomy
100 Clinical Results associated with Redasemtide Trifluoroacetate
Login to view more data
100 Translational Medicine associated with Redasemtide Trifluoroacetate
Login to view more data
100 Patents (Medical) associated with Redasemtide Trifluoroacetate
Login to view more data
100 Deals associated with Redasemtide Trifluoroacetate
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ischemic cardiomyopathyPhase 2
Japan
Shionogi & Co., Ltd.Shionogi & Co., Ltd.
13 Jun 2024
Acute Ischemic StrokePhase 2
United States
Fuji Yakuhin Co., Ltd.Fuji Yakuhin Co., Ltd.
27 Jul 2023
Acute Ischemic StrokePhase 2
United States
Shionogi & Co., Ltd.Shionogi & Co., Ltd.
27 Jul 2023
Acute Ischemic StrokePhase 2
Japan
Shionogi & Co., Ltd.Shionogi & Co., Ltd.
27 Jul 2023
Acute Ischemic StrokePhase 2
Japan
Fuji Yakuhin Co., Ltd.Fuji Yakuhin Co., Ltd.
27 Jul 2023
Acute Ischemic StrokePhase 2
Australia
Fuji Yakuhin Co., Ltd.Fuji Yakuhin Co., Ltd.
27 Jul 2023
Acute Ischemic StrokePhase 2
Australia
Shionogi & Co., Ltd.Shionogi & Co., Ltd.
27 Jul 2023
Acute Ischemic StrokePhase 2
Belgium
Fuji Yakuhin Co., Ltd.Fuji Yakuhin Co., Ltd.
27 Jul 2023
Acute Ischemic StrokePhase 2
Belgium
Shionogi & Co., Ltd.Shionogi & Co., Ltd.
27 Jul 2023
Acute Ischemic StrokePhase 2
Czechia
Shionogi & Co., Ltd.Shionogi & Co., Ltd.
27 Jul 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free